The B cell therapy developer has publicly launched with $50m in series A financing from investors including Illumina Ventures.
US-based cell engineering technology startup Walking Fish Therapeutics emerged from stealth yesterday having completed a $50m series A round that included genomics technology producer Illumina.
Co-investment vehicle Emerson Collective and venture capital firm Quan Capital also participated in the round, while Illumina invested through its corporate venturing unit, Illumina Ventures. The company has not revealed details of its seed funding.
Walking Fish is working on cellular therapies for cancer, rare diseases and autoimmune diseases as well as products focusing on…
